VIEWS: 16 PAGES: 7 POSTED ON: 9/29/2008
Molecular basis of cancer RET Oncogene (GFR). Tyrosine kinase receptor (neurotropic factors) Dimerization & activation; substrate specificity altered. MEN types 2A (thy, adr, parathy), 2B (thy, adr )and familial medullary thyroid carcinoma. Complete loss: Hirschsprung disease. RAS Oncogene Single most common abnormality of dominant oncogenes in human tumors. 90% pancreatic adenoca. K, cholangioca. 50% colon K, endometrial, thyroid. 30% lung adenoca., myeloid leukemias N. Growth factors-EGF, PDGF, CSF-1 Growth factor receptor Activation of RAS GF Cell membrane GFR Inactive RAS Active RAS P Activation of MAP kinase pathway Nucleus Activation of transcription RAS contd.. Signal transducing protein. GTPase-activating proteins (GAPs): brake. Mutations of RAS: brake falters. Neurofibromin NF-1: GAP. BRAF: 80% benign nevi. MYC Oncogene Induced when quiescent cell receives a signal to divide. Histone acety. MYC protein Nucleus ↓ cell adhesion MAX protein Target genes ↑ cell motility ↑ protein synthesis Trascriptional activator: ↓ proteinase activity Ornithine decarboxylase, cyclin D2 MYC contd.. C-MYC : Burkitt lymphoma N-MYC : Neuroblastoma, small cell carcinoma of lung L-MYC : Small cell carcinoma of lung Breast, colon, lung and other Cas.
Pages to are hidden for
"Neoplasia 4a"Please download to view full document